Endometriosis is a chronic inflammatory condition for which existing treatments, mainly hormonal therapy and surgical intervention, remain insufficient. These approaches are often limited by high recurrence rates, significant side effects, and an inability to effectively target underlying disease mechanisms. This review outlines emerging mechanism-oriented therapeutic strategies that combine targeted drug delivery, immunomodulation, and physical ablation. Advanced delivery systems, such as Lipid nanoparticle polymeric carriers, and nanomicelles, enable selective accumulation of therapeutic agents at endometriotic lesions, improving efficacy while minimizing systemic toxicity. Immunomodulatory strategies pursue to re-establish immune balance by enhancing immune surveillance, driving macrophage polarization toward anti-inflammatory states, and suppressing pro-inflammatory signaling, often through nanocarrier-enabled localized delivery. Furthermore, physical ablation techniques including gold (Au) NPs-mediated photothermal therapy and magnetic hyperthermia offer minimally invasive approaches for precise lesion elimination while preserving adjacent healthy tissues. Collectively, integrating these strategies may advance preclinical efforts to improve disease management, patient stratification, and potentially fertility outcomes, although clinical validation is still required. Despite ongoing challenges in clinical translation, the convergence of nanotechnology, immunology and interventional therapy marks a conceptual shift away from symptom-centered management toward investigational strategies that, pending clinical validation, may confer disease-modifying potential in endometriosis.
2 October 2026 in Human Vaccines & Immunotherapeutics
Cancer and infectious diseases remain threat to the global public health system, and there is a pending need to develop more effective immunotherapeutic and prophylactic agents.1 While there have b...
Poor aqueous solubility remains a major challenge in drug development, particularly for Biopharmaceutics Classification System (BCS) class II drugs, whose absorption is limited by solubility and dissolution rate. For BCS class IV drugs, which are additionally restricted by permeability, the benefit of solubility enhancement is less predictable. Pharmaceutical cocrystals are a promising and innovative solid-state approach to improve the biopharmaceutical properties of active pharmaceutical ingredients (APIs) without changing their intrinsic chemical structure and pharmacological identity. This review systematically examines the basic design concepts, the wide range of therapeutic applications, and the mechanism of dissolution enhancement and bioavailability improvement of cocrystals. We discuss the integration of cocrystals into synergistic combination therapies, stimuli-responsive smart delivery systems, and advanced nanoscale formulations that enable targeted and controlled drug release. Despite this, there are significant challenges remaining, such as physiological instability in the gastrointestinal tract, manufacturing scalability and reproducibility, rational coformer selection strategies, and regulatory uncertainty exacerbated by sparse pharmacokinetic information and a lack of understanding regarding cocrystal biological interactions at a molecular level. Bringing cocrystal-based formulations to clinical use will take joint, multidisciplinary, and solution-driven efforts across the disciplines of pharmaceutical sciences, materials chemistry, regulatory science, and clinical pharmacology. Finally, pharmaceutical cocrystals represent a promising platform to address solubility restrictions, with growing evidence, predominantly preclinical, of improved therapeutic performance for poorly soluble drugs.